 SEATTLE, March 31, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC today announced that it has completed a rolling New Drug Application NDA submission to the U.S. Food and Drug Administration FDA seeking approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia platelet counts less than 50 x 109L. CTI had previously announced the results of a pre-NDA meeting with FDA where agreement was reached on an NDA submission package based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 trials. 